The MICs and fractional inhibitory concentrations of posaconazole (POS) and voriconazole (VRZ), alone and in combination with amphotericin B (AMB), for the conidia and hyphae of 100 Aspergillus isolates were evaluated. POS-AMB had more synergistic activity against hyphae (75% of isolates) than VRZ-AMB (37%) and significantly more synergistic activity against hyphae than against conidia (12%).
gistic; FIC Ն1 to Յ4, indifferent; and FIC Ͼ4, antagonistic (3) . Also, the metabolic activity of drug-treated hyphae was determined by their ability to reduce the tetrazolium compound 3-(4,5-dimethl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide (MTT), as described elsewhere (13) . Duplicate testing was performed on separate days. The results of the in vitro tests were compared by the log-rank test. Significance was defined as a P value of Ͻ0.05.
The MIC ranges for conidia and hyphae of Aspergillus spp. are given in Table 1 , and the interaction results are given in Table 2 . The POS-AMB and VRZ-AMB interactions were synergistic to indifferent. The activity of the combination of POS and AMB was significantly more synergistic against hyphae than against conidia. Visual readings of growth inhibition were correlated with the colorimetric assessments of the metabolic activities of fungi. For hyphae, comparison of the visually determined endpoints with the results of the MTT method revealed that 84.7% of the visually determined MICs corresponded to a 95% or greater reduction in metabolic activity, as measured by determination of the optical density.
Our MIC data for POS and VRZ for conidial suspensions of Aspergillus spp. were comparable to those presented in previously published reports (3, 7, 9, 14, 22) . The in vitro activities of POS in combination with AMB against conidia of Aspergillus ranged from indifferent (88% of isolates) to synergistic (12% of isolates). The activity of the VRZ-AMB combination was more equally distributed between indifferent and synergistic (57% and 43%, respectively). The results of a number of in vivo and in vitro studies with the POS-AMB and VRZ-AMB combinations have been published, and all studies showed a lack of antagonism (5, 14, 19, 21) . These data and those from our study suggest evidence of a possible additive and/or synergistic effect. However, antifungal combination therapies are still controversial (16, 19) . Some studies have suggested that azole antifungal agents would antagonize the effects of AMB (16, 20) . Also, in vitro combination tests must evaluate complex events that are difficult to assess (19) . Using the same combinations, different authors have observed a spectrum from antagonism to synergism, depending on the methodology and analysis used (16, 19) . However, the antagonism of the POS-AMB and VRZ-AMB combinations has not been reported so far. The onset of invasive Aspergillus infection is associated with the appearance of hyphae (10) . Consequently, an agent must be active against the hyphal form in order to be clinically effective. POS and VRZ exerted strong activities against the hyphae of Aspergillus spp.; and the POS-AMB combination yielded excellent results, as the FIC indices were synergistic for 75% of isolates. These FIC indices were significantly (P Ͻ 0.05) higher than those for synergistic activity against the conidia (12%). The underlying mechanism for this effect is unknown. Differences in the sterol compositions, the fungal cell membrane transporters, and the cell wall compositions of hyphae and conidia could account for this finding (2). One possible explanation for the synergy could be that polyene (AMB) binding to the fungus destabilizes the membrane and facilitates the entry of the azole (POS or VRZ). Our results suggest that a combination of AMB with POS might be effective against infections due to Aspergillus spp., as shown by Najvar et al. (14) .
Clinical studies confirm that POS has a favorable safety profile during treatment of seriously ill patients with invasive fungal infections (3, 9, 17) . POS appears to be well tolerated (9, 17) , making this substance a promising candidate for use for the prevention and treatment of fungal infections in immunocompromised patients. The lack of antagonism in vitro and in vivo (3, 4, 14, 21) suggests that POS-AMB and VRZ-AMB may be used as combination therapies for the treatment of fungal infections.
In conclusion, POS and VRZ exhibited excellent in vitro activities against the hyphae of Aspergillus spp., and the combination of POS and AMB was significantly more active against hyphae than against conidia (P Ͻ 0.05). Further synergy tests with this drug combination are warranted, and the impact of the combination on patient outcomes needs to be further investigated. 
